Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 1/2 18Phase 3 9Phase 1 8Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 18Gemcitabine 14Carboplatin 14pembrolizumab 13Specimen Handling 13Paclitaxel 13Bevacizumab 11Radiotherapy 10Nivolumab 10atezolizumab 8Radiation 8Platinum 8Doxorubicin 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Pemetrexed 7Drug Therapy 7Dexamethasone 7Temozolomide 6Ipilimumab 6Surgical Procedures, Operative 5Rituximab 5Radiotherapy, Intensity-Modulated 5Prednisone 5Cytarabine 5Cyclophosphamide 5Biopsy 5130-nm albumin-bound paclitaxel 5venetoclax 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × abemaciclib × 90 days × Clear all
NCT03706365 2026-04-24

CYCLONE 2

Eli Lilly and Company

Phase 2/3 Active not recruiting
393 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡